Table 1 Demographic and clinical characteristics of the study population.

From: Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis

 

MTX-m

MTX-1ww

MTX-2ww

 
 

n = 72

n = 71

n = 73

p-value

Age

57 (48–63)

57 (45–67)

56 (47–69)

0.79

Sex (female)

57 (79.2)

58 (81.7)

58 (79.5)

0.92

Ethnicity (White)1

64 (88.9)

63 (88.7)

57 (78.1)

0.24

Comorbidities3

46 (63.9)

35 (49.3)

46 (63)

0.14

Rheumatoid arthritis

59 (81.9)

58 (81.7)

61 (83.6)

0.13

Psoriatic Arthritis

13 (18.1)

13 (18.3)

12 (16.4)

0.95

MTX dose (mg/week)

15 (10–17.5)

15 (10–15)

15 (10–17.5)

0.71

DAS28-CRP2 [0–8.47]

2.3 (1.7–3.2)

2.1 (1.5-3)

2.3 (1.6–3.1)

0.58

CRP (mg/dL) [0–0.5]

0.2 (0.1–0.4)

0.2 (0.1–0.3)

0.2 (0.1–0.5)

0.12

Lymphocyte count (cells/mm3) [1.5 × 103-4.0 × 103]

1865 (1465–2440)

2020 (1520–2440)

2010 (1595–2315)

0.70

Biologic DMARDs

19 (26.4)

22 (31)

26 (35.6)

0.49

TNF inhibitors

16 (22.2)

20 (28.2)

19 (26)

—

IL-6 inhibitors

2 (2.8)

2 (2.8)

5 (6.8)

—

IL-17 inhibitors

1 (1.4)

1 (1.4)

1 (1.4)

—

Rituximab

0 (0)

0 (0)

1 (1.4)

—

Other csDMARDs

12 (16.7)

12 (16.9)

13 (17.8)

0.95

Hydroxycloroquine

5 (6.9)

3 (4.2)

3 (4.1)

—

Sulphasalazine

3 (4.2)

4 (5.6)

3 (4.1)

—

Leflunomide

4 (5.6)

5 (7)

7 (9.9)

—

tsDMARDs

4 (5.6)

3 (4.2)

2 (2.7)

0.65

Tofacitinib

0 (0)

2 (2.8)

0 (0)

—

Baricitinib

4 (5.6)

1 (1.4)

1 (1.4)

—

Upadacitinib

0 (0)

0 (0)

1 (1.4)

—

Glucocorticoids

7 (9.7)

9 (12.7)

13 (17.8)

0.40

Average dose of GC (mg/day)

5 (2.5-10)

3.8 (2.5-6.2)

3.8 (2.5-5)

0.70

Type of vaccine

0.15

One dose of BNT162b2

4 (5.6)

3 (4.2)

9 (12.3)

—

Two doses of BNT162b2

47 (65.3)

44 (62)

46 (63)

—

One dose of ChAdOx-1-S

1 (1.4)

0 (0)

0 (0)

—

Two doses of ChAdOx-1-S

11 (15.3)

13 (18.3)

5 (6.8)

—

One dose of mRNA-1273

0 (0)

1 (1.4)

1 (1.4)

—

Two doses of mRNA-1273

5 (6.9)

1 (1.4)

6 (8.2)

—

One dose of Ad26.COV2.S

4 (5.6)

9 (12.7)

6 (8.2)

—

Days between vaccine doses4

21 (21–115)

21 (21–96)

21 (21–90)

0.91

Days from vaccination completion to blood sampling

28 (28–35)

29 (28–35)

29 (28–35)

0.85

COVID-19 pre-vaccination

18 (25)

10 (14.1)

12 (16.4)

0.21

COVID-19 after 1st dose

3 (4.2)

1 (1.4)

3 (4.1)

—

  1. 1Other ethnicities included: Latin American, North African and Black. 2DAS28 score is an objective measure of disease activity: <2.6 remission; 2.6–3.2 low disease activity; 3.2–5.1 moderate disease activity; >5.1 high disease activity. 3Comorbidities studied: systemic arterial hypertension, diabetes, dyslipidemia, obesity, cardiovascular disease, thromboembolic disease, renal failure, chronic bronchitis, asthma and cancer. 4(Min to max range)
  2. All categorical variables are expressed as absolute count (percentage) and quantitative variables as median (IQR). Statistical significance was determined by using ANOVA or Kruskal Wallis for quantitative and chi-square or Fisher exact test for qualitative variables.
  3. MTX methotrexate, DAS28 disease activity score in 28 joints, CRP C-reactive protein, DMARDs disease-modifying antirheumatic drugs, csDMARDs conventional synthetic DMARDs, tsDMARDs targeted synthetic DMARDs, GC glucocorticoids, COVID-19 coronavirus disease 2019, RA rheumatoid arthritis, PsA psoriatic arthritis.
Back to article page